Pipeline

At Exelixis, our goal is to develop innovative therapies that have first- or best-in-class potential to treat cancer and other serious diseases. We take a focused and pragmatic approach to the drug development process, and are driven by patient need, clinical data, and a strong commitment to advancing breakthrough products.

To achieve this goal we are developing a portfolio of novel compounds targeting key mediators of cancer- and other disease-related pathways. Our discovery research capabilities have generated a solid pipeline of product candidates, several of which are now in broad late-stage development programs. Our integrated development infrastructure leverages strong capabilities in translational research to inform our activities across the development continuum. Rigorous preclinical studies and candidate selection criteria increase our likelihood of success in the clinic, while the evaluation of biomarkers in our clinical trials provides insights that help optimize and streamline our development efforts.

In addition to our internal capabilities, we collaborate with leading pharmaceutical companies to expand our resources, and reach. Currently, we have oncology programs partnered with Bristol-Myers Squibb Company, sanofi-aventis, Genentech (now Roche), and GlaxoSmithKline. Additional partnerships with Bristol-Myers Squibb Company, Pfizer, Daiichi-Sankyo, and Boehringer Ingelheim focus on advancing compounds that have potential utility in cardiovascular, inflammation, and metabolic disease indications